web analytics
1.3 C
Munich
Sunday, November 27, 2022

Propanc Biopharma, Inc. (OTCQB: PPCB) Heating Up as Biotech Confirms no RS as it Advances PRP Targeting Solid Tumors in Cancer

Propanc Biopharma, Inc. (OTCQB: PPCB) saw a significant boost on Friday and reversal off $0.0018 lows after the Company stated they have no plans to affect a reverse split anytime soon. The Company did file a Definitive Information Statement under Section 14C of the Exchange Act on June 9, 2022, to increase the authorized shares of common stock, James Nathanielsz, BAS, MEI, CEO and Chairman at Propanc, believes the increase in authorized shares is necessary for the Company as a result of recent volatile market conditions, which have been broad and far reaching for microcap companies.  

Mr. Nathanielsz went on to say that the team has been working on a long-term plan and vision. Management firmly believes it has put a solid foundation in place to achieve success with its lead product candidate, PRP, as the Company advances towards early-stage clinical development. Management is exploring potential opportunities with strategic partners and clinical researchers to advance the Company’s interests and will update shareholders as things progress. PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Propanc Biopharma, Inc. (OTCQB: PPCB) is a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. Propanc is working with its advisors, to explore ways to restructure and strengthen the Company’s balance sheet to ensure the Company is sufficiently resourced to progress its lead product candidate, PRP. 

PRP is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention. PRP is a combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP produces multiple effects on cancerous cells intended to inhibit tumor growth and potentially stop a tumor from spreading through the body. The Company received notification from the FDA that PRP had been conferred Orphan Drug Designation for the treatment of pancreatic cancer. This special status is granted when a rare disease or condition is implicated and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations. 

To Find out the inside Scoop on PPCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PPCB

 

A Certificate for Advance Overseas Finding was received from the Board of Innovation and Science Australia to receive up to a 43.5% “cash back” benefit from overseas R&D expenses. The finding relates to the planned Phase 1 clinical trial – Multiple Ascending Dose Studies of proteolytic proenzymes for the treatment of advanced cancer patients suffering from solid tumors planned to be conducted at the Peter MacCallum Center, Melbourne, Australia. Overseas activities to be undertaken include the development of an analytical assay for the quantification of active pharmaceutical ingredients in the Company’s lead product candidate, PRP, and its manufacture of the finished product for the Phase 1 clinical trial. 

Propanc’s POP1 joint research and drug discovery program is designed to produce a backup clinical compound to the lead product candidate, PRP. With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between lots and without sourcing the proenzymes from animals, Propanc Biopharma is undertaking a challenging research project in collaboration with the Universities of Jaén and Granada. The Company entered into a second two-year joint research and collaboration agreement with the University of Jaén who are undertaking the research activities for the POP1 program. 

PRP, targets solid tumors, which accounts for 80 – 90% of cancer cases, according to the National Cancer Institute. Chief Scientific Officer and Co-Founder, Dr Julian Kenyon MD, MB, ChB, is leading research into a novel approach to prevent recurrence and metastasis from solid tumors using pancreatic proenzymes that target and eradicate cancer stem cells (CSCs), which are a small subpopulation of cells within tumors capable of self-renewal, differentiation and tumorigenicity when transplanted into an animal host. CSCs is the mechanism by which cancer is able to return and spread, even post standard treatments. 

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading well under a penny at a market valuation of less than $1 million PPCB has just 127 million shares in the float and $133,000 in the treasury with $3 million in debt. The stock got a boost after the Company stated they have no plans to affect a reverse split anytime soon. PPCB was a major runner in the past and certainly has potential at current levels; fully reporting OTCQB PPCB lead product candidate PRP, targets solid tumors, which accounts for 80 – 90% of cancer cases, according to the National Cancer Institute. The Company received notification from the FDA that PRP had been conferred Orphan Drug Designation for the treatment of pancreatic cancer. This special status is granted when a rare disease or condition is implicated and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations. We will be updating on PPCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PPCB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PPCB either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.